These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3053564)

  • 21. Comparison of spiramycin and erythromycin in the treatment of experimental guinea pig legionellosis.
    Dournon E; Rajagopalan P
    J Antimicrob Chemother; 1988 Jul; 22 Suppl B():69-72. PubMed ID: 3182448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute bronchopulmonary infections: treatment with i.v. spiramycin.
    Vachon F; Kernbaum S
    Chemioterapia; 1987 Aug; 6(4):282-5. PubMed ID: 3308147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of spiramycin on the nasopharyngeal carriage of Neisseria meningitidis.
    Engelen F; Vandepitte J; Verbist L; De Maeyer-Cleempoel S
    Chemotherapy; 1981; 27(5):325-33. PubMed ID: 6790232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationships between the sensitivities in vitro of Neisseria gonorrhoeae to spiramycin, penicillin, streptomycin, tetracycline, and erythromycin.
    Reyn A; Bentzon MW
    Br J Vener Dis; 1969 Sep; 45(3):223-7. PubMed ID: 4981352
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparative in-vitro activity of azithromycin, macrolides (erythromycin, clarithromycin and spiramycin) and streptogramin RP 59500 against oral organisms.
    Williams JD; Maskell JP; Shain H; Chrysos G; Sefton AM; Fraser HY; Hardie JM
    J Antimicrob Chemother; 1992 Jul; 30(1):27-37. PubMed ID: 1331019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In-vitro activity of RU 28965, a new macrolide, compared to that of erythromycin.
    Rolston KV; LeBlanc B; Ho DH
    J Antimicrob Chemother; 1986 Feb; 17(2):161-3. PubMed ID: 3700283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative in vitro activities of four macrolides: josamycin, erythromycin, spiramycin and roxithromycin, against 424 anaerobic bacteria.
    Derriennic M; Dubreuil L; Reynaud AE; Courtieu AL
    Chemioterapia; 1987 Jun; 6(2 Suppl):159-60. PubMed ID: 3509376
    [No Abstract]   [Full Text] [Related]  

  • 28. Spiramycin: in-vitro activity on Branhamella catarrhalis.
    Riou JY; Guibourdenche M
    J Antimicrob Chemother; 1988 Jul; 22 Suppl B():53-6. PubMed ID: 3141349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The in vitro activity of roxithromycin (RU 28965) compared with four oral antibiotics.
    Drabu YJ; Mehtar S; Blakemore PH
    Drugs Exp Clin Res; 1987; 13(4):201-3. PubMed ID: 3622250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spiramycin resistance in Staphylococcus aureus. Decrease in spiramycin-accumulation and the ribosomal affinity of spiramycin in resistant staphylococci.
    Shimizu M; Saito T; Hashimoto H; Mitsuhashi S
    J Antibiot (Tokyo); 1970 Feb; 23(2):63-7. PubMed ID: 5416652
    [No Abstract]   [Full Text] [Related]  

  • 31. [Metronidazole and spiramycin, an original antimicrobial combination in odontostomatology].
    Videau D; Laufer J; Mignon H
    Rev Stomatol Chir Maxillofac; 1976 Mar; 77(2):364-9. PubMed ID: 1066752
    [No Abstract]   [Full Text] [Related]  

  • 32. Mechanism of action of spiramycin and other macrolides.
    Brisson-Noël A; Trieu-Cuot P; Courvalin P
    J Antimicrob Chemother; 1988 Jul; 22 Suppl B():13-23. PubMed ID: 3053566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antagonistic interactions of macrolides and synergimycins on bacterial ribosomes.
    Di Giambattista M; Vannuffel P; Sunazuka T; Jacob T; Omura S; Cocito C
    J Antimicrob Chemother; 1986 Sep; 18(3):307-15. PubMed ID: 3095298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergy between spiramycin and metronidazole in the treatment of polymicrobial infections.
    Brook I
    J Antimicrob Chemother; 1988 Jul; 22 Suppl B():77-85. PubMed ID: 3141350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Spiramycin ; therapeutic value in humans. (author's transl)].
    Kernbaum S
    Sem Hop; 1982 Feb; 58(5):289-97. PubMed ID: 6277009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [In vitro activity of roxithromycin against hospital bacteria and the concordance curve].
    Soussy CJ; Chanal M; Kitzis MD; Duval J; Cluzel R; Acar JF
    Pathol Biol (Paris); 1988 May; 36(5):420-4. PubMed ID: 2900488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spiramycin: a reappraisal of its antibacterial activity.
    Sutherland R
    Br J Pharmacol Chemother; 1962 Aug; 19(1):99-110. PubMed ID: 19108164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of the in vitro post-antibiotic effect of C14 macrolides (erythromycin and roxithromycin) and C16 macrolides (josamycin and spiramycin) against Staphylococcus aureus].
    Rolin O; Bouanchaud DH
    Pathol Biol (Paris); 1989 May; 37(5):375-7. PubMed ID: 2780094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [In vitro activity of roxithromycin, new semisynthetic macrolide against obligate anaerobes].
    Dubreuil L; Devos J; Romond C; Bryskier A
    Pathol Biol (Paris); 1986 May; 34(5):440-4. PubMed ID: 3534717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Josamycin: interpretation of inhibition zones with the Bauer-Kirby agar disk diffusion test as compared with erythromycin.
    Karthein J; Spohr M; Traub WH
    Chemotherapy; 1986; 32(4):336-43. PubMed ID: 3731919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.